Literature DB >> 25836941

Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer.

David J McConkey1, Woonyoung Choi2, Andrea Ochoa2, Arlene Siefker-Radtke3, Bogdan Czerniak4, Colin P N Dinney5.   

Abstract

Recent studies revealed that muscle-invasive bladder cancers segregate into intrinsic basal and luminal subtypes that are similar to those described for breast cancer. Each subtype is enriched with potentially clinically actionable genomic alterations and epigenetic signatures; there are associations between tumor subtype and sensitivity to conventional cisplatin-based chemotherapy. The authors review biological and clinical characteristics of the intrinsic subtypes and describe their implications for the development of conventional and targeted agents. The role that tumor plasticity seems to play in basal and luminal bladder cancer biology and its potential effects on the development of therapeutic resistance is also discussed.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Basal and luminal; Neoadjuvant chemotherapy; Urothelial cancer

Mesh:

Substances:

Year:  2015        PMID: 25836941     DOI: 10.1016/j.hoc.2014.11.003

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  21 in total

Review 1.  Toward personalized management in bladder cancer: the promise of novel molecular taxonomy.

Authors:  Marie-Lisa Eich; Lars Dyrskjøt; George J Netto
Journal:  Virchows Arch       Date:  2017-04-21       Impact factor: 4.064

Review 2.  Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.

Authors:  Kenneth M Felsenstein; Dan Theodorescu
Journal:  Nat Rev Urol       Date:  2017-11-14       Impact factor: 14.432

Review 3.  Systemic, perioperative management of muscle-invasive bladder cancer and future horizons.

Authors:  Samuel A Funt; Jonathan E Rosenberg
Journal:  Nat Rev Clin Oncol       Date:  2016-11-22       Impact factor: 66.675

Review 4.  Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.

Authors:  Woonyoung Choi; Andrea Ochoa; David J McConkey; Mattias Aine; Mattias Höglund; William Y Kim; Francisco X Real; Anne E Kiltie; Ian Milsom; Lars Dyrskjøt; Seth P Lerner
Journal:  Eur Urol       Date:  2017-03-30       Impact factor: 20.096

Review 5.  Overview of Current and Future Adjuvant Therapy for Muscle-Invasive Urothelial Carcinoma.

Authors:  Rosa Nadal; Andrea B Apolo
Journal:  Curr Treat Options Oncol       Date:  2018-05-28

6.  SBSN drives bladder cancer metastasis via EGFR/SRC/STAT3 signalling.

Authors:  Zhongqiu Zhou; Zhuojun Zhang; Han Chen; Wenhao Bao; Xiangqin Kuang; Ping Zhou; Zhiqing Gao; Difeng Li; Xiaoyi Xie; Chunxiao Yang; Xuhong Chen; Jinyuan Pan; Ruiming Tang; Zhengfu Feng; Lihuan Zhou; Lan Wang; Jianan Yang; Lili Jiang
Journal:  Br J Cancer       Date:  2022-04-28       Impact factor: 9.075

Review 7.  Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer.

Authors:  Robert T Jones; Kenneth M Felsenstein; Dan Theodorescu
Journal:  Urol Clin North Am       Date:  2015-10-31       Impact factor: 2.241

8.  Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression.

Authors:  Darshan S Chandrashekar; Balabhadrapatruni V S K Chakravarthi; Alyncia D Robinson; Joshua C Anderson; Sumit Agarwal; Sai Akshaya Hodigere Balasubramanya; Marie-Lisa Eich; Akhilesh Kumar Bajpai; Sravanthi Davuluri; Maya S Guru; Arjun S Guru; Gurudatta Naik; Deborah L Della Manna; Kshitish K Acharya; Shannon Carskadon; Upender Manne; David K Crossman; James E Ferguson; William E Grizzle; Nallasivam Palanisamy; Christopher D Willey; Michael R Crowley; George J Netto; Eddy S Yang; Sooryanarayana Varambally; Guru Sonpavde
Journal:  Oncogene       Date:  2020-03-30       Impact factor: 9.867

9.  Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer.

Authors:  Seth P Lerner; Dean F Bajorin; Colin P Dinney; Jason A Efstathiou; Susan Groshen; Noah M Hahn; Donna Hansel; David Kwiatkowski; Michael O'Donnell; Jonathan Rosenberg; Robert Svatek; Jeffrey S Abrams; Hikmat Al-Ahmadie; Andrea B Apolo; Joaquim Bellmunt; Margaret Callahan; Eugene K Cha; Charles Drake; Jonathan Jarow; Ashish Kamat; William Kim; Margaret Knowles; Bhupinder Mann; Luigi Marchionni; David McConkey; Lisa McShane; Nilsa Ramirez; Andrew Sharabi; Arlene H Sharpe; David Solit; Catherine M Tangen; Abdul Tawab Amiri; Eliezer Van Allen; Pamela J West; J A Witjes; Diane Zipursky Quale
Journal:  Bladder Cancer       Date:  2016-04-27

10.  Suppression of progranulin expression inhibits bladder cancer growth and sensitizes cancer cells to cisplatin.

Authors:  Simone Buraschi; Shi-Qiong Xu; Manuela Stefanello; Igor Moskalev; Alaide Morcavallo; Marco Genua; Ryuta Tanimoto; Ruth Birbe; Stephen C Peiper; Leonard G Gomella; Antonino Belfiore; Peter C Black; Renato V Iozzo; Andrea Morrione
Journal:  Oncotarget       Date:  2016-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.